Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Carcinoma, Hepatocellular 22Small Cell Lung Carcinoma 17Lung Neoplasms 14Neoplasms 13Breast Neoplasms 9Colorectal Neoplasms 7Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Melanoma 5Carcinoma, Transitional Cell 5Uterine Cervical Neoplasms 4Sarcoma 4Neoplasm Metastasis 4Glioblastoma 4Stomach Neoplasms 3Solid Tumors 3Sarcoma, Alveolar Soft Part 3Liver Neoplasms 3Extensive Stage Lung Small Cell Carcinoma 3Endometrial Neoplasms 3Carcinoma 3Treatment-Refractory Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2

Interventions

Etoposide 2Carboplatin 2tislelizumab 1lutetium Lu 177 dotatate 1atezolizumab 1Injections 1Cisplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × atezolizumab × 90 days × Clear all
NCT05142696 2026-05-29

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Novartis

Phase 1/2 Active not recruiting
24 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡